Wednesday, 14 October 2020
MUMBAI: Epygen Biotech, a biopharma company with operations in Mumbai and Dubai, has tied up with US-based biotech firm Dyadic to work on a potential Covid-19 vaccine, reports Rupali Mukherjee.
Epygen along with Dyadic plans to offer 500 million doses of an “affordable’’ vaccine within six months of completing human trials, Epygen founder and CEO Debayan Ghosh told TOI. Epygen joins the list of domestic firms which includes Bharat Biotech, Serum Institute and Zydus Cadila in the race to develop a vaccine. At present, Epygen has a capacity of producing around 20-40 million doses a month. Dyadic has developed a vaccine antigen from its patented C1 cell line.